Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OMCL 
Omnicell Inc (OMCL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: OMCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44
1 Year Target Price $44
| 3 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.86% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.42B USD | Price to earnings Ratio 61.66 | 1Y Target Price 44 |
Price to earnings Ratio 61.66 | 1Y Target Price 44 | ||
Volume (30-day avg) 8 | Beta 0.78 | 52 Weeks Range 22.66 - 55.74 | Updated Date 08/12/2025 |
52 Weeks Range 22.66 - 55.74 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 0.2622 | Actual 0.45 |
Profitability
Profit Margin 2.01% | Operating Margin (TTM) 2.8% |
Management Effectiveness
Return on Assets (TTM) 0.49% | Return on Equity (TTM) 1.87% |
Valuation
Trailing PE 61.66 | Forward PE 29.5 | Enterprise Value 1388929958 | Price to Sales(TTM) 1.23 |
Enterprise Value 1388929958 | Price to Sales(TTM) 1.23 | ||
Enterprise Value to Revenue 1.21 | Enterprise Value to EBITDA 13.52 | Shares Outstanding 45934300 | Shares Floating 44824020 |
Shares Outstanding 45934300 | Shares Floating 44824020 | ||
Percent Insiders 1.81 | Percent Institutions 104.98 |
Upturn AI SWOT
Omnicell Inc
Company Overview
History and Background
Omnicell Inc. was founded in 1992. Initially focused on medication dispensing automation, it has grown through innovation and acquisitions to become a leading provider of medication management and adherence solutions for healthcare systems and pharmacies.
Core Business Areas
- Medication Management Solutions: Provides automated dispensing systems, inventory management software, and analytics to improve medication management in hospitals and other healthcare facilities.
- Medication Adherence Solutions: Offers solutions for retail and specialty pharmacies, including adherence packaging, automation, and patient engagement tools, aimed at improving patient adherence to medication regimens.
Leadership and Structure
The leadership team includes Randall Lipps (Chairman, President, and CEO). The company has a typical corporate structure with departments focused on sales, marketing, R&D, operations, and finance.
Top Products and Market Share
Key Offerings
- XT Automated Dispensing Cabinets: Automated medication dispensing system used in hospitals. Competitors include BD (Becton, Dickinson and Company), Capsa Healthcare and Swisslog Healthcare. Market share for Omnicell ADC estimated at approximately 20-25%.
- Central Pharmacy Automation: Solutions for central pharmacies to automate medication compounding, packaging, and dispensing. Competitors include iRxFill, ARxIUM, and RxSafe.
- EnlivenHealth: Patient engagement and adherence platform for retail pharmacies. Competitors include Amplicare, PrescribeWellness, and Outcome Health.
Market Dynamics
Industry Overview
The healthcare automation market is growing due to increasing labor costs, medication errors, and the need for improved efficiency in healthcare facilities. The market is driven by technological advancements, regulatory requirements, and the growing geriatric population.
Positioning
Omnicell is a leading provider of medication management and adherence solutions, positioned to capitalize on the growing demand for automation in healthcare. It competes on innovation, product breadth, and customer service.
Total Addressable Market (TAM)
Estimated at $10-15 billion globally. Omnicell is positioned to address a significant portion of this TAM through its comprehensive product portfolio.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Strong customer relationships
- Established market presence
- Innovative technology
- Acquisition Strategy
Weaknesses
- Integration challenges from acquisitions
- High debt levels
- Dependence on hospital capital spending
- Product recalls
- Cybersecurity Risk
Opportunities
- Expanding into new geographic markets
- Developing new medication adherence solutions
- Increasing adoption of automation in pharmacies
- Growing demand for remote pharmacy services
- Partnerships with healthcare providers and payers
Threats
- Increased competition
- Regulatory changes
- Economic downturn
- Technological obsolescence
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- BDX
- Baxter
- ARX
Competitive Landscape
Omnicell competes with larger companies that have broader product portfolios. Its strengths lie in specialized expertise in medication management and a focus on innovation.
Major Acquisitions
ReCept Pharmacy
- Year: 2021
- Acquisition Price (USD millions): 290
- Strategic Rationale: Expanded Omnicell's presence in the 340B market.
Performance Analytics (PAAS)
- Year: 2021
- Acquisition Price (USD millions): 185
- Strategic Rationale: Acquisition provided advanced analytics and business intelligence solutions for pharmacy operations.
Growth Trajectory and Initiatives
Historical Growth: Omnicell's historical growth has been driven by a combination of organic expansion and strategic acquisitions.
Future Projections: Analysts project continued revenue growth driven by increasing demand for automation in healthcare and expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of new medication adherence solutions, expansion of cloud-based services, and strategic acquisitions to expand product offerings and market reach.
Summary
Omnicell is a prominent player in the medication management and adherence solutions market, benefiting from increasing demand for healthcare automation. However, high debt and acquisition integration could be issues. To capitalize on growth, Omnicell must manage its debt, streamline operations, and maintain a strong focus on innovation. Increased competition and economic pressures are important external risks to consider.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omnicell Inc
Exchange NASDAQ | Headquaters Fort Worth, TX, United States | ||
IPO Launch date 2001-08-07 | Founder, Executive Chairman, President & CEO Mr. Randall A. Lipps | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3650 | Website https://www.omnicell.com |
Full time employees 3650 | Website https://www.omnicell.com | ||
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.